A Eriksson1, M Shafazand, E Jennische, S Lange. 1. Dept. of Internal Medicine, Sahlgren's University Hospital, Göteborg, Sweden. anders.s.eriksson@vgregion.se
Abstract
BACKGROUND: The antisecretory factor (AF) is a 41 kD endogenously produced protein capable of mediating protection against diarrhoea diseases and intestinal inflammation. High concentrations of AF-like proteins are present in egg yolk, and AF can consequently be administrated in the form of egg yolk drinks. In this study, performed in patients suffering from acute onset of ulcerative colitis (UC), we evaluate the influence of orally administrated AF on the histological and clinical laboratory outcome. METHODS: A total of 20 patients fulfilled this prospective, double-blind and randomized protocol. The intake of AF was used as an additive treatment to conventional UC medication. Patient registrations were extended to two outward visits, performed 2-4 and 8-12 weeks after hospital discharge. RESULTS: During AF treatment, a reduction in the histological severity from mucosal biopsies received from the mid-rectum was found. In addition, a lowering in the inflammatory blood parameters ESR, CRP and orosomucoid was demonstrated. CONCLUSION: In the AF-treated group a late and significant lowering of various inflammatory parameters combined with a histological recovery was demonstrated. These findings suggest that administration of AF mediates a long-lasting anti-inflammatory effect in cases of acute UC.
RCT Entities:
BACKGROUND: The antisecretory factor (AF) is a 41 kD endogenously produced protein capable of mediating protection against diarrhoea diseases and intestinal inflammation. High concentrations of AF-like proteins are present in egg yolk, and AF can consequently be administrated in the form of egg yolk drinks. In this study, performed in patients suffering from acute onset of ulcerative colitis (UC), we evaluate the influence of orally administrated AF on the histological and clinical laboratory outcome. METHODS: A total of 20 patients fulfilled this prospective, double-blind and randomized protocol. The intake of AF was used as an additive treatment to conventional UC medication. Patient registrations were extended to two outward visits, performed 2-4 and 8-12 weeks after hospital discharge. RESULTS: During AF treatment, a reduction in the histological severity from mucosal biopsies received from the mid-rectum was found. In addition, a lowering in the inflammatory blood parameters ESR, CRP and orosomucoid was demonstrated. CONCLUSION: In the AF-treated group a late and significant lowering of various inflammatory parameters combined with a histological recovery was demonstrated. These findings suggest that administration of AF mediates a long-lasting anti-inflammatory effect in cases of acute UC.
Authors: Shirin Ilkhanizadeh; Hanna Sabelström; Yekaterina A Miroshnikova; Aaron Frantz; Wen Zhu; Aurora Idilli; Jon N Lakins; Christin Schmidt; David A Quigley; Trenten Fenster; Edith Yuan; Jacqueline R Trzeciak; Supna Saxena; Olle R Lindberg; Janna K Mouw; Jason A Burdick; Sergey Magnitsky; Mitchel S Berger; Joanna J Phillips; Daniele Arosio; Dandan Sun; Valerie M Weaver; William A Weiss; Anders I Persson Journal: Mol Cancer Res Date: 2018-02-05 Impact factor: 5.852
Authors: Nur H Alam; Hasan Ashraf; Maryam Olesen; Mohammed A Salam; Niklaus Gyr; Remy Meier Journal: J Health Popul Nutr Date: 2011-08 Impact factor: 2.000
Authors: Virginia Bazzurro; Elena Gatta; Elena Angeli; Aroldo Cupello; Stefan Lange; Eva Jennische; Mauro Robello; Alberto Diaspro Journal: Eur J Neurosci Date: 2022-07-20 Impact factor: 3.698
Authors: Joakim Strandberg; Catarina Lindquist; Stefan Lange; Fredrik Asztely; Eric Hanse Journal: Front Cell Neurosci Date: 2014-01-28 Impact factor: 5.505